225 related articles for article (PubMed ID: 17980352)
1. Agonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cells.
Huang P; Xu W; Yoon SI; Chen C; Chong PL; Unterwald EM; Liu-Chen LY
Brain Res; 2007 Dec; 1184():46-56. PubMed ID: 17980352
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells.
Huang P; Xu W; Yoon SI; Chen C; Chong PL; Liu-Chen LY
Biochem Pharmacol; 2007 Feb; 73(4):534-49. PubMed ID: 17141202
[TBL] [Abstract][Full Text] [Related]
3. Brain region-specific N-glycosylation and lipid rafts association of the rat mu opioid receptor.
Huang P; Chen C; Xu W; Yoon SI; Unterwald EM; Pintar JE; Wang Y; Chong PL; Liu-Chen LY
Biochem Biophys Res Commun; 2008 Jan; 365(1):82-8. PubMed ID: 17980152
[TBL] [Abstract][Full Text] [Related]
4. Localization of the kappa opioid receptor in lipid rafts.
Xu W; Yoon SI; Huang P; Wang Y; Chen C; Chong PL; Liu-Chen LY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1295-306. PubMed ID: 16505160
[TBL] [Abstract][Full Text] [Related]
5. Subcellular localization of mu-opioid receptor G(s) signaling.
Chakrabarti S; Chang A; Gintzler AR
J Pharmacol Exp Ther; 2010 Apr; 333(1):193-200. PubMed ID: 20097777
[TBL] [Abstract][Full Text] [Related]
6. GRIN1 regulates micro-opioid receptor activities by tethering the receptor and G protein in the lipid raft.
Ge X; Qiu Y; Loh HH; Law PY
J Biol Chem; 2009 Dec; 284(52):36521-36534. PubMed ID: 19861419
[TBL] [Abstract][Full Text] [Related]
7. Chronic opioid treatment augments caveolin-1 scaffolding: relevance to stimulatory μ-opioid receptor adenylyl cyclase signaling.
Chakrabarti S; Chang A; Liu NJ; Gintzler AR
J Neurochem; 2016 Dec; 139(5):737-747. PubMed ID: 27726130
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.
Sally EJ; Xu H; Dersch CM; Hsin LW; Chang LT; Prisinzano TE; Simpson DS; Giuvelis D; Rice KC; Jacobson AE; Cheng K; Bilsky EJ; Rothman RB
Synapse; 2010 Apr; 64(4):280-8. PubMed ID: 19953652
[TBL] [Abstract][Full Text] [Related]
9. Agonist-selective signaling is determined by the receptor location within the membrane domains.
Zheng H; Chu J; Qiu Y; Loh HH; Law PY
Proc Natl Acad Sci U S A; 2008 Jul; 105(27):9421-6. PubMed ID: 18599439
[TBL] [Abstract][Full Text] [Related]
10. Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure.
Chakrabarti S; Regec A; Gintzler AR
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):217-24. PubMed ID: 15857684
[TBL] [Abstract][Full Text] [Related]
11. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
12. Adenylyl cyclase superactivation induced by long-term treatment with opioid agonist is dependent on receptor localized within lipid rafts and is independent of receptor internalization.
Zhao H; Loh HH; Law PY
Mol Pharmacol; 2006 Apr; 69(4):1421-32. PubMed ID: 16415176
[TBL] [Abstract][Full Text] [Related]
13. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells.
Hirota K; Okawa H; Appadu BL; Grandy DK; Devi LA; Lambert DG
Anesthesiology; 1999 Jan; 90(1):174-82. PubMed ID: 9915326
[TBL] [Abstract][Full Text] [Related]
15. Mu opioid receptor efficacy and potency of morphine-6-glucuronide in neonatal guinea pig brainstem membranes: comparison with transfected CHO cells.
Gray RE; Munks MW; Haynes RR; Olsen GD
Brain Res Bull; 2001 Mar; 54(5):499-505. PubMed ID: 11397539
[TBL] [Abstract][Full Text] [Related]
16. Mu-opioid receptor splice variants: sex-dependent regulation by chronic morphine.
Verzillo V; Madia PA; Liu NJ; Chakrabarti S; Gintzler AR
J Neurochem; 2014 Sep; 130(6):790-6. PubMed ID: 24848866
[TBL] [Abstract][Full Text] [Related]
17. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
18. Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine.
Wang HY; Burns LH
PLoS One; 2009; 4(1):e4282. PubMed ID: 19172190
[TBL] [Abstract][Full Text] [Related]
19. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
20. Caveolae as potential mediators of MCH-signaling pathways.
Cook LB; Delorme-Axford EB; Robinson K
Biochem Biophys Res Commun; 2008 Oct; 375(4):592-5. PubMed ID: 18722347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
